Attention-deficit hyperactivity disorder (Q57400259)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023516%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Attention-deficit hyperactivity disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023516%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

attention deficit hyperactivity disorder

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023516%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1

Joseph Biederman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023516%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

1 July 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023516%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023516%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

366

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023516%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

237-248

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023516%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

9481

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023516%20AND%20SRC:MED&resulttype=core&format=json

The history of adult attention-deficit/hyperactivity disorder.

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

International consensus statement on ADHD. January 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Globalisation of international health

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Family factors and sampling approach differentially influence attention deficit/hyperactivity disorder subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Validity of DSM-IV subtypes of attention-deficit/hyperactivity disorder: a family study perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Validity of DSM-IVADHD subtypes in a nationally representative sample of Australian children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Familial clustering of latent class and DSM-IV defined attention-deficit/hyperactivity disorder (ADHD) subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

[Frequency, comorbidity and psychosocial correlates of attention-deficit/hyperactivity disorder. Results of a Bremen adolescent study]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Family study of girls with attention deficit hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The truth about quality: medical usefulness and analytical reliability of laboratory tests

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Correspondence of parent and teacher reports in medication trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Young adults with attention deficit hyperactivity disorder: subtype differences in comorbidity, educational, and clinical history.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Psychiatric comorbidity associated with DSM-IV ADHD in a nonreferred sample of twins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The comorbidity of ADHD in the general population of Swedish school-age children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Antecedents of opioid dependence and personality disorder: attention-deficit/hyperactivity disorder and conduct disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Injuries to children with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Clinical course of attention-deficit/hyperactivity disorder from childhood toward early adolescence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Social impairment in girls with ADHD: patterns, gender comparisons, and correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

ADHD comorbidity findings from the MTA study: comparing comorbid subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Occult mood disorders in 104 consecutively presenting children referred for the treatment of attention-deficit/hyperactivity disorder in a community mental health clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Gender effects on attention-deficit/hyperactivity disorder in adults, revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Trends in the prescribing of psychotropic medications to preschoolers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

National trends in the treatment of attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The use of methylphenidate in children: analysis of prescription usage based in routine data of the statutory health insurance bodies concerning drug prescriptions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Use of psychostimulant medication for ADHD in South Australia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Stimulant treatment for children: a community perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychostimulant treatment rates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

ADHD treatment in a behavioral health care carve-out: medications, providers, and service utilization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Children in special education programs: attention deficit hyperactivity disorder, use of services, and unmet needs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Ethnic and regional differences in primary care visits for attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The nature and heritability of attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Molecular genetics of attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Adoptive and biological families of children and adolescents with ADHD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Attention-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Neurobiology of attention-deficit hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Linkage disequilibrium mapping at DAT1, DRD5 and DBH narrows the search for ADHD susceptibility alleles at these loci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Dopamine transporter density in patients with attention deficit hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Coloboma hyperactive mutant mice exhibit regional and transmitter-specific deficits in neurotransmission.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The Effect of Sugar on Behavior or Cognition in Children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Impact of low birth weight on attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Behavioral outcomes and evidence of psychopathology among very low birth weight infants at age 20 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Psychiatric symptoms and disorders in adolescents with low birth weight

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Psychopathology and Social Competencies of Adolescents Who Were Extremely Low Birth Weight

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Birth insult interacts with stress at adulthood to alter dopaminergic function in animal models: possible implications for schizophrenia and other disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Attention deficit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Twelve-year follow-up of children exposed to alcohol in utero.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Effects of prenatal alcohol exposure at school age. II. Attention and behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Prenatal alcohol exposure and sustained attention in the preschool years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Effect of antenatal exposure to maternal smoking on behavioural problems and academic achievement in childhood: prospective evidence from a Dutch birth cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Detrimental effects of prenatal cocaine exposure: illusion or reality?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Prenatal nicotine alters nicotinic receptor development in the mouse brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Effects of prenatal nicotine exposure on rat striatal dopaminergic and nicotinic systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Attainment and adjustment in two geographical areas. I--The prevalence of psychiatric disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Family-environment risk factors for attention-deficit hyperactivity disorder. A test of Rutter's indicators of adversity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Differential effect of environmental adversity by gender: Rutter's index of adversity in a group of boys and girls with and without ADHD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Outcome, prognosis, and risk in a longitudinal follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Depressed mothers as informants about their children: a critical review of the evidence for distortion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The biochemical basis of minimal brain dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The nucleus accumbens motor-limbic interface of the spontaneously hypertensive rat as studied in vitro by the superfusion slice technique

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Are planning, working memory, and inhibition associated with individual differences in preschool ADHD symptoms?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Neuropsychological functioning in children with DSM-IV combined type Attention Deficit Hyperactivity Disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

How specific are executive functioning deficits in attention deficit hyperactivity disorder and autism?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Impaired spatial working memory in adults with attention-deficit/hyperactivity disorder: comparisons with performance in adults with borderline personality disorder and in control subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The top and the bottom of ADHD: a neuropsychological perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Executive functioning, temporal discounting, and sense of time in adolescents with attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge Neuropsychological Test Automated

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The unity and diversity of executive functions and their contributions to complex "Frontal Lobe" tasks: a latent variable analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Attention-deficit/hyperactivity disorder (ADHD) behaviour explained by dysfunctioning reinforcement and extinction processes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The cognitive-energetic model: an empirical approach to attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Temperament and attention deficit hyperactivity disorder: the development of a multiple pathway model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Differential patterns of striatal activation in young children with and without ADHD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Etiology and pathogenesis of attention-deficit hyperactivity disorder (ADHD): significance of prematurity and perinatal hypoxic-haemodynamic encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Stimulant treatment of adult attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Stimulant medications precipitate Tourette's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

The 4-Year Course of Tic Disorders in Boys With Attention-Deficit/Hyperactivity Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Treatment of ADHD in children with tics: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Methylphenidate and growth in hyperactive children. A controlled withdrawal study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Growth of Hyperactive Children Treated With Methylphenidate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Slowing of growth in height and weight on stimulants: a characteristic pattern

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Daily methylphenidate use slows the growth of children: a community based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A comparison of sustained-release bupropion and placebo for smoking cessation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Combining methylphenidate and clonidine: a clinically sound medication option

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Parenting and family stress treatment outcomes in attention deficit hyperactivity disorder (ADHD): an empirical analysis in the MTA study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Deficient inhibition as a marker for familial ADHD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Evaluating the endophenotype model of ADHD neuropsychological deficit: results for parents and siblings of children with ADHD combined and inattentive subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

Waxing and waning in concert: dynamic comorbidity of conduct disorder with other disruptive and emotional problems over 7 years among clinic-referred boys.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966915-2

7 January 2021

10.1016/S0140-6736(05)66915-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023516%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference